Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep, they flushed out the weak
hands, it's time to go back up.
Get ready for lift off brothers
Drop your pant$$ fill em bid$$$ I want em all$$$
Is EL-22 a CRISPR/Cas9-based therapy platform
Churn and burn brothers
Made in the USA brother, Rock and roll
You've got that right brother,
may they burn in hell.
It’s their last hurrah, blue skies coming…
The billion dollar fat burner is coming…
The shorts are trapped to cover
Cash infusion with sale and give or take they worth at least $5 a share now. Give it a few days
…..The purchase consideration for the Acquisition is as follows:
• Approximately $1.1 million in Carmell common stock at the closing of the Acquisition (the “Closing”);
• Approximately $57,000 in cash upon the sale of specified inventory existing as of the Closing;
• Contingent earnout consideration consisting of:
• 5% of net sales from Elevai’s existing products paid annually during the 5-year period following the Closing, and
• a one-time milestone payment of $500,000 if Elevai’s hair and scalp products achieve $500,000 in net revenue within 24 months following the Closing; and
• Carmell’s assumption of contractual liabilities and trade payables of Elevai at the Closing.
As part of the Acquisition, Carmell expects to acquire the following assets of Elevai:
• Product portfolio with trailing twelve-month revenue of approximately $2.5 million;
• Commercial and product development team;
• Finished and work-in-process inventory of approximately $1.0 million; and
• Accounts receivable of approximately $0.03 million.
Said Mr. Rajiv Shukla, Chairman of Carmell, “This acquisition will integrate one of the newest advances in stem cell derived exosome technology into the Carmell platform, further cementing our status as the home of the best bio-aesthetic skincare science, Built by Biology just as Nature intended.”….,,
......(the “Acquisition”).
Boom boom News selling skincare tonCTCX
All this while Shorty keeps
pulling it down.
This won't last.
Believers push for the last day of the year moving forward to a brand new year… anything can happen… Rags to the riches$$ FDA fast track approval
i smell forest green✅
New years miracle up ahead dudes!!
Many metric tons have been
praying for this miracle.
Fatzzo fat ass miracle
ELAB DRUG Move brothers
That's one very ambitious offering brother,
We know what is coming. 😉
RNAZ ELAB APVO 2025🐳🐳🐳🐳🐳Attack
Pharma whales soaking up the float
Elevai Labs (ELAB) Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
December 9, 2024 8:03 AM
Elevai Labs Inc. (Nasdaq: ELAB) (“Elevai” or the “Company”), a diversified holding company, subsidiary Elevai Biosciences Inc. (“Elevai Biosciences”), today announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass.
In collaboration with KCRN Research, Inc., the Company is preparing for a pre-IND meeting with the FDA, anticipated in the first quarter of 2025. This meeting will establish the development pathway for EL-22, clarifying any additional preclinical requirements and adjustments to Chemistry, Manufacturing, and Controls before IND submission.
EL-22 is an engineered probiotic designed to express myostatin on its surface, leveraging the myostatin pathway to support muscle health. Preclinical studies, including a 2022 study in mdx mice (a model of Duchenne muscular dystrophy), demonstrated significant physiological and functional improvements.1 EL-22 has also completed a Phase 1 clinical trial in South Korea, where it was shown to be generally well tolerated and safe in healthy volunteers.
“Regulatory precedent for myostatin-based therapies in combination with GLP-1 receptor agonists are promising,” said Deniel Mero, Co-founder of Elevai Biosciences. “Leveraging existing data from our Korean licensing partner, including human safety studies, provides a strong foundation to accelerate the IND process and subsequent U.S. clinical trials. We are excited about EL-22’s potential to redefine obesity care by combining effective weight loss with muscle preservation.”
Elevai aims to file the IND in 2025 and thereafter initiate clinical trials to evaluate the combination of EL-22 with GLP-1 receptor agonists for obesity treatment.
About Elevai Labs, Inc.
Elevai Labs Inc. specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
About Elevai Biosciences
Elevai Biosciences Inc., an Elevai Labs company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.elevaibio.com.
We need extremely hungry whales,
to go on a feeding frenzy.
2025 🐳🐳🐳🐳🐳🐳🐳🐳🐳🐳 Yesr of the whales
Get ready brother!! Whales 🐳 🐳🐳🐳🐳
Just spotted a pharma whale brother, buyout on open market
Merry Christmas brother, and a
prosperous new year.
Human trials got approved in Korea
You've got that right.
The North American market
is HUGE, for there's a lot of
BLUBBER to get rid of.😄
All the fat asses in america will look like models in no time 100$
Now, PMGC HOLDINGS INC.
Bring it on
News is out for you fat head weight loss brother
1 was wrong unless they put something out this afternoon.
1 was posting yesterdag "" buy all you can news tomorrow ""
If news would have been announced, we would be sitting over $4
news that never come
where is the news for today ????